Efficient inhibition of ovarian cancer by degradable nanoparticle-delivered survivin T34A gene

References

• TorreLABrayFSiegelRLGlobal cancer statistics, 2012CA Cancer J Clin20156528710825651787
   PubMed Web of Science ®Google Scholar
• BanerjeeSKayeSBNew strategies in the treatment of ovarian cancer: current clinical perspectives and future potentialClin Cancer Res201319596196823307860
   PubMed Web of Science ®Google Scholar
• SiegelRLMillerKDJemalACancer statistics, 2015CA Cancer J Clin201565152925559415
   PubMed Web of Science ®Google Scholar
• LeboulchPGene therapy: primed for take-offNature2013500746228028223955226
   PubMedGoogle Scholar
• WaltherWSchlagPMCurrent status of gene therapy for cancerCurr Opin Oncol201325665966424100345
   PubMed Web of Science ®Google Scholar
• O’ConnorDMBoulisNMGene therapy for neurodegenerative diseasesTrends Mol Med201521850451226122838
   PubMed Web of Science ®Google Scholar
• BongianinoRPrioriSGGene therapy to treat cardiac arrhythmiasNat Rev Cardiol201512953154625917154
   PubMedGoogle Scholar
• GinnSLAlexanderIEEdelsteinMLGene therapy clinical trials worldwide to 2012 – an updateJ Gene Med2013152657723355455
   PubMed Web of Science ®Google Scholar
• YinHKanastyRLEltoukhyAANon-viral vectors for gene-based therapyNat Rev Genet201415854155525022906
   PubMed Web of Science ®Google Scholar
• GiaccaMZacchignaSVirus-mediated gene delivery for human gene therapyJ Control Release2012161237738822516095
   PubMed Web of Science ®Google Scholar
• ThomasCEEhrhardtAKayMAProgress and problems with the use of viral vectors for gene therapyNat Rev Genet20034534635812728277
   PubMed Web of Science ®Google Scholar
• RamamoorthMNarvekarANon viral vectors in gene therapy – an overviewJ Clin Diagn Res201591GE01GE0625738007
   PubMed Web of Science ®Google Scholar
• MintzerMASimanekEENonviral vectors for gene deliveryChem Rev2009109225930219053809
   PubMed Web of Science ®Google Scholar
• KunathKvon HarpeAFischerDLow-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimineJ Control Release200389111312512695067
   PubMed Web of Science ®Google Scholar
• GouMMenKZhangJEfficient inhibition of C-26 colon carcinoma by VSVMP gene delivered by biodegradable cationic nanogel derived from polyethyleneimineACS Nano20104105573558420839784
   PubMed Web of Science ®Google Scholar
• LiuPGouMYiTEfficient inhibition of an intraperitoneal xenograft model of human ovarian cancer by HSulf-1 gene delivered by biodegradable cationic heparin-polyethyleneimine nanogelsOncol Rep201227236337022086394
   PubMedGoogle Scholar
• YangFGouMDengHEfficient inhibition of ovarian cancer by recombinant CXC chemokine ligand 10 delivered by novel biodegradable cationic heparin-polyethyleneimine nanogelsOncol Rep201228266867622684947
   PubMedGoogle Scholar
• AmbrosiniGAdidaCAltieriDCA novel anti-apoptosis gene, survivin, expressed in cancer and lymphomaNat Med1997389179219256286
   PubMed Web of Science ®Google Scholar
• StauberRHMannWKnauerSKNuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potentialCancer Res200767135999600217616652
   PubMed Web of Science ®Google Scholar
• AspeJRWallNRSurvivin-T34A: molecular mechanism and therapeutic potentialOnco Targets Ther2010324725421289859
   PubMed Web of Science ®Google Scholar
• McKayTRBellSTenevTProcaspase 3 expression in ovarian carcinoma cells increases survivin transcription which can be countered with a dominant-negative mutant, survivin T34A; a combination gene therapy strategyOncogene200322233539354712789262
   PubMed Web of Science ®Google Scholar
• SunICEunDKNaJHHeparin-coated gold nanoparticles for liver-specific CT imagingChemistry20091548133411334719902441
   PubMedGoogle Scholar
• BonoFDe SmetFHerbertCInhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric propertiesCancer Cell201323447748823597562
   PubMedGoogle Scholar
• BoussifOLezoualc’hFZantaMAA versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimineProc Natl Acad Sci U S A19959216729773017638184
   PubMed Web of Science ®Google Scholar
• LungwitzUBreunigMBlunkTPolyethylenimine-based non-viral gene delivery systemsEur J Pharm Biopharm200560224726615939236
   PubMed Web of Science ®Google Scholar
• ZhangJWuDXingZN-isopropylacrylamide-modified polyethylenimine-mediated p53 gene delivery to prevent the proliferation of cancer cellsColloids Surf B Biointerfaces2015129546225829127
   PubMed Web of Science ®Google Scholar
• ChoWYHongSHSinghBSuppression of tumor growth in lung cancer xenograft model mice by poly(sorbitol-co-PEI)-mediated delivery of osteopontin siRNAEur J Pharm Biopharm20159445046226141346
   PubMed Web of Science ®Google Scholar
• NguyenHKLemieuxPVinogradovSVEvaluation of polyether-polyethyleneimine graft copolymers as gene transfer agentsGene Ther20007212613810673718
   PubMed Web of Science ®Google Scholar
• MitaACMitaMMNawrockiSTSurvivin: key regulator of mitosis and apoptosis and novel target for cancer therapeuticsClin Cancer Res200814165000500518698017
   PubMed Web of Science ®Google Scholar
• SamarasingheRMGibbonsJKanwarRKNanotechnology based platforms for survivin targeted drug discoveryExpert Opin Drug Discov20127111083109222950742
   PubMed Web of Science ®Google Scholar
• AltieriDCSurvivin, cancer networks and pathway-directed drug discoveryNat Rev Cancer200881617018075512
   PubMed Web of Science ®Google Scholar
• MiyazakiAKobayashiJTorigoeTPhase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancerCancer Sci2011102232432921143701
   PubMed Web of Science ®Google Scholar
• GiacconeGZatloukalPRoubecJMulticenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancerJ Clin Oncol200927274481448619687333
   PubMed Web of Science ®Google Scholar
• MobahatMNarendranARiabowolKSurvivin as a preferential target for cancer therapyInt J Mol Sci20141522494251624531137
   PubMed Web of Science ®Google Scholar
• Vivas-MejiaPERodriguez-AguayoCHanHDSilencing survivin splice variant 2B leads to antitumor activity in taxane – resistant ovarian cancerClin Cancer Res201117113716372621512144
   PubMedGoogle Scholar
• HuQLiWHuXSynergistic treatment of ovarian cancer by co-delivery of survivin shRNA and paclitaxel via supramolecular micellar assemblyBiomaterials201233276580659122717365
   PubMed Web of Science ®Google Scholar
• MehtaAZhangLBoufraqechMInhibition of survivin with YM155 induces durable tumor response in anaplastic thyroid cancerClin Cancer Res201521184123413225944801
   PubMedGoogle Scholar
• AltieriDCValidating survivin as a cancer therapeutic targetNat Rev Cancer200331465412509766
   PubMed Web of Science ®Google Scholar
• PanLPengXCLengFTherapeutic effects of survivin dominant negative mutant in a mouse model of prostate cancerJ Cancer Res Clin Oncol20111371192820217127
   PubMedGoogle Scholar
• O’ConnorDSSchechnerJSAdidaCControl of apoptosis during angiogenesis by survivin expression in endothelial cellsAm J Pathol2000156239339810666367
   PubMed Web of Science ®Google Scholar